Award Recognition:
Frost & Sullivan has awarded Wedge Pharmaceutical's Microecological Probiotics Sector (Wedge Pharma) the "Global Intestinal Product Leadership Award" and the "Global Gynecological Microecology Therapy Technology Innovation Leadership Award." The awards recognize Wedge Pharma's outstanding performance in technology innovation, market potential, and branding within the global microecology market.

Company Overview:
Wedge Pharma, a core segment of Shenzhen-listed Wedge (Stock Code: 000534), is a leading enterprise in China's microecology therapeutics and female health sectors. It holds the distinction of being China's only microecology formulation company with national high-tech qualifications in both digestive and gynecological therapeutic fields.

Core Products & Market Impact:
The company’s success is driven by a dual-product strategy:

1. "Golden Bifid" (Jin Shuangqi): A national Class I new drug and one of China’s first approved microecology formulations. It is a leading brand in gastrointestinal microecology therapy, widely used in pediatrics, gastroenterology, geriatrics, and ICUs, with a reputation for high efficacy, safety, and compliance. It has served over 100 million patients.
2. "Ding Jun Sheng": The globally exclusive live vaginal microecology product, offering a novel therapeutic pathway for gynecological health. It addresses vaginal infections by restoring microbial balance and enhancing biological resistance, providing an alternative to traditional antibiotic treatments.

R&D and Industrial Strategy:
Wedge Pharma has built a comprehensive, integrated industrial system over three decades, focusing on deep "production, study, research, and medical use" integration. Key initiatives include:

• Research Collaboration: Partnering with top-tier institutions to build national academic platforms and a full-chain research system from basic research to evidence-based medicine.
• Industrial Expansion: Constructing two international-standard biomedicine manufacturing bases in Zhuhai High-tech Zone and Hohhot, forming a coordinated north-south production layout.
• Innovation Frontier: Actively expanding into Live Biotherapeutic Products (LBPs). Its invested innovative four-strain gynecological drug is currently in Phase III clinical trials. The Shenzhen-based Wedge Microbiology Research Institute strengthens R&D capabilities from bacterial strain selection to clinical translation.

Corporate Honors:
The company is a certified member of the International Scientific Association for Probiotics and Prebiotics (ISAPP), has contributed to national pharmacopoeia standards, and has been repeatedly recognized by China’s Ministry of Industry and Information Technology (MIIT) as one of the "Most Investment-Attractive Enterprises in China's Pharmaceutical Industry."

Forward Outlook:
Through these strategic initiatives, Wedge Pharma is advancing its strategic upgrading in the LBP sector, consolidating its long-term fundamentals, and driving high-quality growth in China's microecology industry.